Please ensure Javascript is enabled for purposes of website accessibility

Opko Buys into OAO Pharmsynthez

By Rich Smith - Apr 18, 2013 at 10:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Companies will partner on marketing Opko products in Russia and adjacent countries, and work together on R&D.

Miami, Fl.-based Opko Health (OPK 0.32%) took a 10% stake in Russian peer pharmaceutical firm OAO Pharmsynthez, Opko announced Thursday.

Like the name sounds, Pharmsynthez is a drugmaker and, in fact, the only life sciences company currently trading on the Moscow Stock Exchange. (The "OAO" simply refers to the Russian words for "joint stock company," the Russian designation for a public corporation). It manufactures and sells branded pharmaceutical products, primarily in Russia and the Baltics.

Opko described its stake-purchase as part of a $60 million, two-stage financing project, whereby Russian state-owned corporation Russian Corporation of Nanotechnologies first invested $26.1 million in Pharmsynthez, followed by Opko's larger investment.

Going forward, Opko plans to partner with Pharmsynthez in the development and marketing of several of its own products for sale in Russia and other East European countries, specifically:

  • CTAP101 Capsules, a vitamin D prohormone to treat secondary hyperparathyroidism  in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency
  • several diagnostic products utilizing OPKO's point of care platform
  • Opko's "4Kscore," panel of kallikrein biomarkers used in the detection of prostate cancer

The companies will also collaborate on R&D projects.

Investors appeared to view Thursday's announcement with some skepticism, however, bidding down Opko shares by precisely 1%, to close at $6.95.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
OPK
$3.10 (0.32%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.